Network pharmacology-based mechanism of combined leech and bear bile on hepatobiliary diseases
10.16438/j.0513-4870.2024-0662
- VernacularTitle:基于网络药理学对水蛭与熊胆联用与肝胆相关疾病作用关系的研究
- Author:
Chen GAO
1
;
Yu-shi GUO
2
,
3
;
Xin-yi GUO
1
;
Ling-zhi ZHANG
1
;
Guo-hua YANG
4
;
Yu-sheng YANG
4
;
Tao MA
2
;
Hua SUN
1
Author Information
1. Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, National Key Laboratory of Digestive Health, Beijing
2. School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing
3. Baotou Kundulun District Hospital, Baotou
4. Yunnan Century Huabao Pharmaceutical Industry Development Co., Ltd., Chuxiong
- Publication Type:Research Article
- Keywords:
leech;
bear bile;
network pharmacology;
lipid deposition;
HepG2 cell
- From:
Acta Pharmaceutica Sinica
2025;60(1):105-116
- CountryChina
- Language:Chinese
-
Abstract:
In order to explore the possible role and molecular mechanism of the combined action of leech and bear bile in liver and gallbladder diseases, this study first used network pharmacology methods to screen the components and targets of leech and bear bile, as well as the related target genes of liver and gallbladder diseases. The selected key genes were subjected to interaction network and GO/KEGG enrichment analysis. Then, using sodium oleate induced HepG2 cell lipid deposition model and DL-ethionine induced mouse fatty liver model, the activity of leech and bear bile alone and in combination in reducing liver fat was evaluated in vitro and in vivo, and the expression of key pathway related proteins suggested by network pharmacology was detected by Western blot. The results of network pharmacology analysis showed that the active ingredients of leech and bear bile have 295 intersecting targets with liver and gallbladder related diseases, involving more than 200 signaling pathways, including the PI3K/Akt signaling pathway and phospholipase D signaling pathway closely related to glucose and lipid metabolism. The results of in vitro validation experiments showed that both leech and bear bile, alone and in combination, can significantly inhibit the lipid deposition induced by sodium oleate in human liver cells, reduce the triacylglycerol level in cell culture supernatant, and inhibit the lipid content in liver cells. The observation results of Nile red staining confocal microscopy showed that the combination of leech and bear bile had better activity in reducing lipid deposition in liver cells compared to using them alone. In a mouse fatty liver model, the combination of leech and bear bile can better reduce elevated organ indices, blood lipids, and liver lipid levels, as well as lower the levels of serum liver injury biomarkers. The animals used in this experiment and related disposal meet the requirements of animal welfare. Before the experiment, it was reviewed and approved by IACUC, Institute of Materia Medica, Chinese Academy of Medical Sciences. The Western blot experiment results showed that the combination of leech and bear bile can significantly upregulate the expression levels of p-PI3K and p-Akt proteins, and increase the p-PI3K/PI3K and p-Akt/Akt ratios, which is consistent with the predicted results of network pharmacology. The combination of leech and bear bile has great potential for treating fatty liver disease, and activating the PI3K/Akt pathway may be one of the important mechanisms for reducing lipid deposition in liver cells.
